Brown Advisory Inc. boosted its holdings in shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) by 6.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 573,465 shares of the biopharmaceutical company’s stock after purchasing an additional 35,630 shares during the quarter. Brown Advisory Inc. owned approximately 0.85% of Alder BioPharmaceuticals worth $7,025,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Legal & General Group Plc boosted its position in Alder BioPharmaceuticals by 2.6% during the second quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 400 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in Alder BioPharmaceuticals by 1.9% during the second quarter. The Manufacturers Life Insurance Company now owns 37,488 shares of the biopharmaceutical company’s stock worth $430,000 after purchasing an additional 698 shares in the last quarter. Voya Investment Management LLC boosted its position in Alder BioPharmaceuticals by 8.4% during the second quarter. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 1,734 shares in the last quarter. Russell Investments Group Ltd. boosted its position in Alder BioPharmaceuticals by 7.2% during the second quarter. Russell Investments Group Ltd. now owns 42,416 shares of the biopharmaceutical company’s stock worth $486,000 after purchasing an additional 2,837 shares in the last quarter. Finally, Teachers Advisors LLC boosted its position in Alder BioPharmaceuticals by 3.8% during the second quarter. Teachers Advisors LLC now owns 84,705 shares of the biopharmaceutical company’s stock worth $970,000 after purchasing an additional 3,091 shares in the last quarter. Institutional investors own 96.88% of the company’s stock.

In related news, insider Mark James Litton sold 16,519 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $10.80, for a total value of $178,405.20. Following the completion of the sale, the insider now owns 116,451 shares of the company’s stock, valued at $1,257,670.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 10.60% of the stock is currently owned by company insiders.

Shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) opened at $10.90 on Tuesday. Alder BioPharmaceuticals, Inc. has a fifty-two week low of $8.60 and a fifty-two week high of $25.45.

Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.21) by $0.29. During the same period last year, the firm posted ($0.70) earnings per share. equities analysts forecast that Alder BioPharmaceuticals, Inc. will post -5.36 EPS for the current fiscal year.

A number of brokerages have commented on ALDR. BidaskClub raised Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Credit Suisse Group set a $11.00 target price on Alder BioPharmaceuticals and gave the company a “hold” rating in a report on Thursday, August 24th. Canaccord Genuity began coverage on Alder BioPharmaceuticals in a report on Thursday, October 26th. They set a “buy” rating and a $20.00 target price for the company. Needham & Company LLC reissued a “buy” rating and set a $26.00 target price (down previously from $36.00) on shares of Alder BioPharmaceuticals in a report on Thursday, August 10th. Finally, Royal Bank Of Canada began coverage on Alder BioPharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $17.00 target price for the company. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $28.07.

TRADEMARK VIOLATION WARNING: “Alder BioPharmaceuticals, Inc. (ALDR) Holdings Boosted by Brown Advisory Inc.” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/alder-biopharmaceuticals-inc-aldr-holdings-boosted-by-brown-advisory-inc/1744367.html.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Institutional Ownership by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.